Citigroup’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-100
Closed 7999
2019
Q1
$0 Hold
100
﹤0.01% 8043
2018
Q4
$0 Hold
100
﹤0.01% 8064
2018
Q3
$0 Hold
100
﹤0.01% 8044
2018
Q2
$0 Hold
100
﹤0.01% 7934
2018
Q1
$0 Hold
100
﹤0.01% 7871
2017
Q4
$0 Sell
100
-1,604
-94% -$6.98K ﹤0.01% 7827
2017
Q3
$7K Buy
1,704
+34
+2% +$138 ﹤0.01% 6800
2017
Q2
$5K Buy
1,670
+936
+128% +$3.88K ﹤0.01% 6776
2017
Q1
$7K Buy
734
+134
+22% +$1.18K ﹤0.01% 6724
2016
Q4
$5K Sell
600
-250
-29% -$2.3K ﹤0.01% 6957
2016
Q3
$10K Sell
850
-2,744
-76% -$31.9K ﹤0.01% 6559
2016
Q2
$45K Sell
3,594
-11,420
-76% -$139K ﹤0.01% 5644
2016
Q1
$152K Buy
15,014
+2,044
+16% +$24K ﹤0.01% 5345
2015
Q4
$292K Buy
12,970
+6,218
+92% +$127K ﹤0.01% 4389
2015
Q3
$112K Sell
6,752
-6,973
-51% -$140K ﹤0.01% 4900
2015
Q2
$309K Sell
13,725
-521
-4% -$12.8K ﹤0.01% 4107
2015
Q1
$367K Sell
14,246
-5,713
-29% -$145K ﹤0.01% 4020
2014
Q4
$435K Buy
19,959
+10,670
+115% +$219K ﹤0.01% 4010
2014
Q3
$176K Buy
9,289
+254
+3% +$5.1K ﹤0.01% 4327
2014
Q2
$211K Buy
9,035
+6,066
+204% +$150K ﹤0.01% 4086
2014
Q1
$100K Sell
2,969
-1,273
-30% -$42.9K ﹤0.01% 4992
2013
Q4
$125K Buy
+4,242
New +$77.7K ﹤0.01% 5069

Citigroup's OMED Position: Q2 2019 in Review

Citigroup sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 100 shares.

Citigroup first reported a position in OMED in Q4 2013 and held it in 22 quarters. The position peaked at $435K in Q4 2014. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.

  • Citigroup reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Citigroup sold 100 OncoMed Pharmaceuticals, Inc. shares in Q2 2019.
  • Citigroup first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 22 quarters.
  • Citigroup's OncoMed Pharmaceuticals, Inc. position peaked at $435K in Q4 2014.
  • 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.

Based on Citigroup's 13F filing for Q2 2019, filed 12 Aug 2019.